maraviroc 300 MG Oral Tablet [Selzentry]
maraviroc
RxCUI: 729203
What the CMS Formulary Data Shows for maraviroc 300 MG Oral Tablet [Selzentry]
Per the CMS 2026 Part D formulary file, maraviroc 300 MG Oral Tablet [Selzentry] (RxNorm concept RXCUI 729203, generic name maraviroc) appears on 4 distinct formulary files spanning 18 Medicare Part D plan offerings - 0.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.
Real-world access to maraviroc 300 MG Oral Tablet [Selzentry] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 75% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,674 Part D beneficiaries filled maraviroc 300 MG Oral Tablet [Selzentry] in 2023, with total plan-and-beneficiary spending of $19,093,491 and an average per-beneficiary annual cost of $11,405.91. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry maraviroc 300 MG Oral Tablet [Selzentry] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 18
- Coverage rate
- 0.4%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 75% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,674
- Total spending
- $19,093,491
- Avg per beneficiary
- $11,405.91
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering maraviroc 300 MG Oral Tablet [Selzentry]
18 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Platino Blindao (HMO D-SNP) | TRIPLE S ADVANTAGE, INC. | T1 | No | $0 | PR |
| Platino Enlace (HMO D-SNP) | TRIPLE S ADVANTAGE, INC. | T1 | No | $0 | PR |
| PLATINO ADVANCE (HMO D-SNP) | TRIPLE S ADVANTAGE, INC. | T1 | No | $0 | PR |
| PLATINO PLUS (HMO D-SNP) | TRIPLE S ADVANTAGE, INC. | T1 | No | $0 | PR |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
| Óptimo Plus (PPO) | TRIPLE S ADVANTAGE, INC. | T5 | No | $0 | PR |
| Contigo Plus (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T5 | No | $0 | PR |
| Brillante (HMO-POS) | TRIPLE S ADVANTAGE, INC. | T5 | No | $0 | PR |
| Enlace Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T5 | No | $0 | PR |
| ContigoEnMente (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T5 | No | $0 | PR |
| Ahorro Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T5 | No | $0 | PR |
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $47.00 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | No | $79.70 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T5 | No | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T5 | No | $112.70 | PA |
Frequently Asked Questions
Is maraviroc 300 MG Oral Tablet [Selzentry] covered by Medicare Part D?
Yes, maraviroc 300 MG Oral Tablet [Selzentry] is covered by 18 Medicare Part D plans (0.4% of all Part D formularies).
What tier is maraviroc 300 MG Oral Tablet [Selzentry] on Medicare Part D plans?
maraviroc 300 MG Oral Tablet [Selzentry] averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 5.
Does maraviroc 300 MG Oral Tablet [Selzentry] require prior authorization?
0% of Part D formularies require prior authorization for maraviroc 300 MG Oral Tablet [Selzentry]. Step therapy: 0%. Quantity limits: 75%.
How much does Medicare spend on maraviroc 300 MG Oral Tablet [Selzentry]?
In 2023, total Medicare Part D spending on maraviroc 300 MG Oral Tablet [Selzentry] was $19,093,491, covering 1,674 beneficiaries. The average spend per beneficiary was $11,405.91.
Read our methodology - how this data is sourced, computed, and verified.